Am Fam Physician. 2007 Jan 1;75(1):31.
to the editor: I read the article on the treatment of irritable bowel syndrome (IBS) by Drs. Hadley and Gaarder with great interest.1 Although the information was extensive and well referenced, it missed an important facet of the current understanding and treatment of IBS. The incidence of postinfectious inflammatory bowel disease (7 to 34 percent) has been well studied since the mid-1990s. These patients and patients with long-standing IBS show evidence of a motility disturbance of the nocturnal housekeeper stripping wave of the small intestine with subsequent overgrowth of the innate small intestinal bacteria.2 Therefore, a new approach to the treatment of IBS is being applied by gastroenterologists.
Small intestinal bacterial overgrowth (SIBO) is indicated by a positive lactulose breath test in 10 to 85 percent of patients with IBS. Disruption of the normal small bowel bacterial population appears to result in symptoms of gas, bloating, flatulence, and altered bowel function, often in response to food intake. Several randomized, double-blind, and open-label studies have demonstrated the potential benefit of antibiotics, including the nonabsorbed antibiotic rifaximin (Xifaxan) for the treatment of SIBO in patients with IBS and functional bowel syndrome.3–6 Furthermore, antibiotics are the only pharmacotherapy identified to date to confer sustained clinical benefit beyond cessation of therapy in a randomized, double-blind, placebo-controlled clinical trial of patients with IBS.4 The potential benefits of nonabsorbed antibiotics in the management of IBS should be considered.
REFERENCESshow all references
1. Hadley SK, Gaarder SM. Treatment of irritable bowel syndrome. Am Fam Physician. 2005;72:2501–6....
2. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002;47:2639–43.
3. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–9.
4. Pimentel M, Park S, Kong Y, Wade R, Kane SV. Rifaximin, a nonabsorbable antibiotic improves the symptoms of irritable bowel syndrome: a double-blind, randomized, controlled study [abstract]. Abstracts of the 70th Annual Scientific Meeting of the American College of Gastroenterology, October 30–November 2, 2005, Honolulu, Hawaii, USA. Am J Gastroenterol. 2005;100(9 suppl):S234
5. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;22:31–5.
6. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–33.
editor's note: This letter was sent to the authors of “Treatment of Irritable Bowel Syndrome,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions